Our Commitment
We are committed to improving the health of people affected by chronic inflammatory and fibrotic diseases.
Learn More
Our Company
We are focused on developing and commercializing medicines that treat inflammatory and fibrotic diseases by targeting the endocannabinoid system.
Our Science
We are at the forefront of developing rationally-designed molecules that target the endocannabinoid system to modulate inflammation and fibrosis.
Learn MoreEndocannabinoid System Platform has Potential to Deliver Pipeline of Products
2
Lead Compounds
3
Ongoing Late-Stage Clinical Studies
700+
Compounds in Library
>350k
People Affected by Target Diseases
Join Our Team
We are high achievers, creative, innovative and above all else, passionate about what we do.
View Open Positions
View All News
Recent News
Investor Information
CRBP
Nasdaq
Volume
Market Cap
Change